As the Department of Health and Human Services considers changes to the federal 340B drug program, including switching mandatory drug manufacturer contributions from discounts to rebates, it is important for policymakers to recognize the myriad concerns with this program.
On March 5, Speaker Ryan moderated a panel on tax policy with AEI’s Alex Brill and Kyle Pomerleau.
Alex Brill and Christy Robinson look at the US biosimilars market a decade after the first biosimilar approval.
During much of 2024, the prevailing view in Washington was that some policies related to pharmacy benefit managers (PBMs) would be included in the end-of-year continuing resolution.
The individual provisions of the Tax Cuts and Jobs Act (TCJA) are set to expire at the end of 2025. The Republican-controlled Congress intends to extend these tax cuts but some Republican lawmakers are demanding changes.
